Sage Therapeutics, Inc. (NASDAQ:SAGE) Expected to Post Earnings of -$1.98 Per Share

Wall Street analysts predict that Sage Therapeutics, Inc. (NASDAQ:SAGE) will announce ($1.98) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Ten analysts have made estimates for Sage Therapeutics’ earnings. The lowest EPS estimate is ($2.60) and the highest is ($1.42). Sage Therapeutics reported earnings of ($2.44) per share during the same quarter last year, which indicates a positive year over year growth rate of 18.9%. The firm is scheduled to report its next earnings report before the market opens on Tuesday, May 4th.

On average, analysts expect that Sage Therapeutics will report full-year earnings of ($7.92) per share for the current financial year, with EPS estimates ranging from ($10.21) to ($6.32). For the next financial year, analysts forecast that the firm will report earnings of ($5.93) per share, with EPS estimates ranging from ($9.27) to ($2.02). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Sage Therapeutics.

Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Tuesday, May 4th. The biopharmaceutical company reported ($1.64) EPS for the quarter, topping analysts’ consensus estimates of ($1.98) by $0.34. Sage Therapeutics had a negative net margin of 7,706.84% and a negative return on equity of 63.81%. The business had revenue of $1.58 million during the quarter, compared to the consensus estimate of $2.03 million. During the same quarter in the previous year, the firm posted ($2.44) EPS. The firm’s revenue was down 30.8% on a year-over-year basis.

Several analysts have commented on the stock. TheStreet upgraded shares of Sage Therapeutics from a “d-” rating to a “c-” rating in a research note on Friday, March 19th. Morgan Stanley lowered their price target on shares of Sage Therapeutics from $87.00 to $81.00 and set an “equal weight” rating for the company in a research report on Monday, April 26th. HC Wainwright reaffirmed a “neutral” rating and issued a $86.00 price target (up previously from $74.00) on shares of Sage Therapeutics in a research report on Thursday, February 25th. Piper Sandler began coverage on shares of Sage Therapeutics in a research report on Wednesday, April 7th. They issued an “overweight” rating and a $100.00 price target for the company. Finally, Royal Bank of Canada cut shares of Sage Therapeutics from an “outperform” rating to a “sector perform” rating and increased their target price for the company from $83.00 to $86.00 in a research report on Monday, January 4th. They noted that the move was a valuation call. Eight equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $86.69.

NASDAQ:SAGE traded down $7.82 during trading hours on Tuesday, reaching $71.14. The company had a trading volume of 1,078,172 shares, compared to its average volume of 495,029. Sage Therapeutics has a 52 week low of $33.82 and a 52 week high of $98.39. The firm has a market cap of $4.16 billion, a price-to-earnings ratio of -7.00 and a beta of 2.23. The firm’s 50 day moving average price is $76.05 and its 200-day moving average price is $79.12.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC raised its holdings in shares of Sage Therapeutics by 22.2% in the fourth quarter. Janus Henderson Group PLC now owns 1,978,811 shares of the biopharmaceutical company’s stock worth $171,190,000 after buying an additional 359,110 shares during the last quarter. Artisan Partners Limited Partnership increased its stake in shares of Sage Therapeutics by 11.1% in the fourth quarter. Artisan Partners Limited Partnership now owns 1,592,933 shares of the biopharmaceutical company’s stock worth $137,805,000 after acquiring an additional 159,484 shares during the period. Jennison Associates LLC increased its stake in shares of Sage Therapeutics by 28.7% in the fourth quarter. Jennison Associates LLC now owns 563,968 shares of the biopharmaceutical company’s stock worth $48,789,000 after acquiring an additional 125,603 shares during the period. Norges Bank acquired a new stake in shares of Sage Therapeutics in the fourth quarter worth $44,045,000. Finally, Artal Group S.A. increased its stake in shares of Sage Therapeutics by 79.9% in the fourth quarter. Artal Group S.A. now owns 400,000 shares of the biopharmaceutical company’s stock worth $34,604,000 after acquiring an additional 177,700 shares during the period.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases.

Featured Story: Why is insider trading harmful?

Get a free copy of the Zacks research report on Sage Therapeutics (SAGE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.